UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission file number 000-55572

 

 

 

GREY CLOAK TECH INC.
(Exact name of registrant as specified in its charter)
     
Nevada   47-2594704
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
10300 W. Charleston, Las Vegas, NV   89135
(Address of principal executive offices)   (Zip Code)
     
(702) 201-6450
(Registrant's telephone number, including area code)

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the previous 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No 

 
 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer   Accelerated filer  

Non-accelerated filer

(Do not check if a smaller reporting company)

 

Smaller reporting company

Emerging growth company

 

 ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of May 21, 2020, there were 250,859,759 shares of common stock, $0.001 par value, issued and outstanding.

 
 
 
 

GREY CLOAK TECH INC.

 

TABLE OF CONTENTS 

 

      Page
PART I – FINANCIAL INFORMATION   1
     
  Item 1. Financial Statements   1
  Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   18
  Item 3. Quantitative and Qualitative Disclosure About Market Risks   23
  Item 4. Controls and Procedures   23
       
       
PART II – OTHER INFORMATION   24
     
  Item 1. Legal Proceedings   24
  Item 1A. Risk Factors   24
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   24
  Item 3. Defaults Upon Senior Securities   25
  Item 4. Mine Safety Disclosures   25
  Item 5. Other Information   25
  Item 6. Exhibits   26
       
SIGNATURES   27

 

 
 

PART I – FINANCIAL INFORMATION

 

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider” or similar expressions are used.

 

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

 

 -1-

 Table of Contents

ITEM 1 Financial Statements

 

GREY CLOAK TECH INC

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

    MARCH 31,   DECEMBER 31,
    2019   2018
ASSETS                
                 
CURRENT ASSETS                
   Cash   $ 339,650     $ 485  
   Accounts receivable     27,157       —    
   Inventory     2,343,828       500  
   Note receivable     —         79,295  
   Accrued interest receivable     —         4,762  
Total current assets     2,710,635       85,042  
                 
   Fixed assets, net of accumulated depreciation of $1,614 and $1,351, respectively     22,096       726  
   Website, net of accumulated amortization of $2,800 and $8,540, respectively     —         —    
   Trademarks     —         —    
   Deposit     —         —    
   Goodwill     193,260       —    
Total other assets     215,356       726  
                 
TOTAL ASSETS   $ 2,925,991     $ 85,768  
                 
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
                 
LIABILITIES                
 Accounts payable   $ 46,100     $ 57,340  
 Accounts payable - related party     —         15,000  
 Notes payable     —         63,000  
 Notes payable - related party     1,050,700       —    
 Convertible debt, net of discount of $0.00 and $371,484, respectively     166,750       654,453  
 Convertible debt - related party, net of discount of $0.00 and $16,371, respectively     166,543       61,223  
 Accrued interest payable     477,457       83,899  
 Accrued interest payable - related party     2,519       1,750  
 Derivative liabilities     772,004       2,713,319  
Total current and total liabilities     2,682,073       3,649,984  
                 
                 
STOCKHOLDERS' DEFICIT                
     Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and 1,333,334 shares issued and outstanding, respectively     —         1,333  
     Common stock, $0.001 par value, 2,500,000,000 shares authorized, 121,060,085 and 6,455 shares issued and outstanding, respectively     121,610       6,455  
   Additional paid-in capital     9,542,603       7,440,895  
   Accumulated deficit     (9,420,295 )     (11,012,899 )
Total stockholders' deficit     243,918       (3,564,216 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT   $ 2,925,991     $ 85,768  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 -2-

 Table of Contents

GREY CLOAK TECH INC

CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE MONTH ENDING MARCH 31, 2019 AND 2018

(Unaudited)

 

    2019   2018
         
REVENUE   $ 97,273     $ 19,856  
                 
COST OF REVENUE     31,763       14,699  
                 
GROSS PROFIT     65,509       5,157  
                 
OPERATING EXPENSES                
    General and administrative     262,516       232,064  
                 
Total operating expenses     262,516       232,064  
                 
OTHER INCOME (EXPENSE)                
    Interest expense, net of interest income     (12,864 )     (408,467 )
    Change in fair value on derivative     1,749,436       1,097,469  
    Loss on extinguishment of debt     53,038       (526,481 )
    Gain on sale of asset     —         —    
                 
Total other income (expense)     1,789,611       162,521  
                 
Net loss before income tax provision     1,592,604       (64,386 )
                 
Income tax provision     —         —    
                 
NET LOSS   $ 1,592,604     $ (64,386 )
                 
                 
Loss per share - basic and diluted   $ 0.02     $ (0.00 )
                 
Weighted average number of shares outstanding - basic and diluted     76,552,964       364,956,165  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 -3-

 Table of Contents

 GREY CLOAK TECH INC

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

FOR THE MONTH ENDING MARCH 31, 2019 AND 2018

(Unaudited)

 

            Additional        
    Preferred Stock   Common Stock   Paid-In   Accumulated    
    Shares   Amount   Shares   Amount   Capital   Deficit   Total
                             
Balance - December 31, 2017     1,333,334     $ 1,333       898,422     $ 900     $ 6,502,022     $ (7,683,382 )   $ (1,179,127 )
                                                         
Issuance of common stock for debt conversion     —         —         5,556,932       5,555       920,453       —         926,008  
                                                         
Debt Forgiveness     —         —         —         —         18,420       —         18,420  
                                                         
Net loss for the period     —         —         —         —         —         (3,329,517 )     (3,329,517 )
                                                         
Balance - December 31, 2018     1,333,334       1,333       6,455,354       6,455       7,440,895     $ (11,012,899 )   $ (3,564,216 )
                                                         
Adjustment to issuance of common stock for debt conversion     —         —         —         —         149,700       —         149,700  
                                                         
Cashless exercise of warrants     —         —         996,052       996       1,921       —         2,917  
                                                         
Issuance of shares acquisition of BergaMet     —         —         97,409,678       97,410       1,850,784               1,948,194  
                                                         
Issuance of common stock for preferred stock conversion     (1,333,334 )     (1,333 )     15,592,986       15,593       (14,260 )     —         —    
                                                         
Issuance of common stock for debt conversion     —         —         806,015       806       106,912       —         107,718  
                                                         
Issuance of common stock for consulting fees     —         —         350,000       350       6,650       —         7,000  
                                                         
Debt Forgiveness     —         —         —         —         —         —         —    
                                                         
Net loss for the period     —         —         —         —         —         1,592,604       1,592,604  
                                                         
Balance - March 31, 2019     0       0       121,610,085       121,610       9,542,603     $ (9,420,295 )   $ 243,918  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 -4-

 Table of Contents

GREY CLOAK TECH INC

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE MONTH ENDING MARCH 31, 2019 AND 2018

(Unaudited)

 

    2019   2018
Cash Flows from Operating Activities:                
Net Loss   $ 1,592,604     $ (64,386 )
                 
Adjustments to reconcile net loss to net cash                
used in operating activities:                
Depreciation and amortization     1,614       4,769  
Warrants issued for services     7,000       —    
Non-cash compensation     108,260       934,995  
Change in fair value on derivative liability     (1,941,315 )     (1,097,469 )
Loss on extinguishment of debt     53,038       —    
Gain on sale of asset     —         —    
Impairment of asset     —         —    
Changes in operating assets and liabilities:                
Accounts receivable     (27,157 )     13,836  
Inventory     (2,343,328 )     8,180  
Prepaid expenses     —         —    
Accrued interest receivable     4,762       (782 )
Deposits     —         (1,500 )
Accounts payable     (11,240 )     (33,643 )
Accounts payable - related party     (15,000 )     30,923  
Accrued payroll and taxes     —         —    
Accrued interest payable     393,558       16,523  
Accrued interest payable - related party     769       370  
Net Cash used in Operating Activities     (2,176,435 )     (188,184 )
                 
Cash Flows from Investing Activities:                
                 
Purchase of fixed assets     (22,985 )     —    
Purchase of website     —         —    
Purchase of note receivable     79,295       —    
Cash acquired     —         —    
Purchase of BergaMet     1,907,010       —    
Cash received from sale of asset     —         —    
Payments of note receivable     —         —    
Cash flows provided by (used in) Investing Activities:     1,963,321       —    
                 
Cash Flows from Financing Activities:                
                 
Proceeds from issuance of convertible debt,     (71,092 )     194,583  
Payments for repayment of convertible debt     (349,330 )     —    
Proceeds from issuance of noted payable     (63,000 )     —    
Proceeds from issuance of noted payable - related party     1,050,700       —    
Payments for repayment of notes payable - related party     (15,000 )     —    
Liabilities assumed     —         —    
Net Cash provided by Financing Activities     552,278       194,583  
                 
Increase (decrease) in cash     339,165       6,399  
Cash at beginning of period     485       81,653  
Cash  at end of period   $ 339,650     $ 88,052  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 -5-

 Table of Contents

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

  

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Grey Cloak Tech Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014. The Company has acquired Eqova Life Sciences and is transitioning its business towards marketing and selling CBD oil products. The Company has additionally acquired BergaMet NA, LLC which markets and sells heath supplemental products.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2019 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2018 filed with the SEC on April 1, 2020.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Cash

 

Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value.

 

Accounts Receivables

 

Accounts receivables are recorded at the invoice amount and do not bear interest.

 

Sharerails Note Receivable and Accrued Interest

 

On January 1, 2019, the Company decided to write off the money loaned to Sharerails as being not collectible. The amount written off was $84,057.06.

 

 -6-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Inventory

 

Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost or market. An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to expiration dates.

 

Property and Equipment

 

The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations.

 

Goodwill

 

In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. The Company sees the goodwill to have a ten-year useful life. No goodwill impairment was recognized during the quarter ending March 31, 2019.

 

Revenue Recognition

 

Beginning January 1, 2019, the Company implemented ASC 606, Revenue from Contracts with Customers.  Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities within them.  These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

 

 -7-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services.  To achieve this core principle, we apply the following five steps:  identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

 

The Company records revenue upon shipment of the products to the customers.

 

Concentration

 

There is no concentration of revenue for the year ended December 31, 2018 and the quarter ended March 31, 2019 because the revenue was earned from multiple customers. One customer accounted for 100% of total revenue earned during the year ended December 31, 2017.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. As of March 31, 2019, the Company did not have any amounts recorded pertaining to uncertain tax positions.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

 -8-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of

unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis.

 

The change in Level 3 financial instrument is as follows:

 

Balance, January 1, 2019   $ 2,713,319  
Issued during the three months ended March 31, 2019     173,947  
Change in fair value recognized in operations     (437,574 )
Converted during the three months ended March 31, 2019     (1,677,688 )
Balance, March 31, 2019   $ 772,004  

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.

 

 -9-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation.

 

We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them.

 

Convertible Instruments

 

The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. During the three months ending March 31, 2019, the Company recognized a gain on extinguishment of $394,208 from the conversion of convertible debt with a bifurcated conversion option.

 

 -10-


GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Common Stock Purchase Warrants

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required.

 

Gain on Extinguishment of debt

 

Note Satisfaction Agreements

 

Prior to the Exchange, the Company entered into a Note Satisfaction Agreement with each of Auctus Fund, Crown Bridge Partners, LLC, Power Up Lending Group Ltd., GS Capital Partners LLC, Oakmore Opportunity Fund I LP, and Adar Bays, LLC. All of these entities were holders of the Company’s convertible debt, and these Note Satisfaction Agreements terminate their convertible notes unless the Company fails to perform its payment obligations. The Company agreed to pay these note holders an aggregate of $518,486 plus interest. The Company paid an aggregate of $353,908 on or before February 15, 2019, and it will pay another $164,578 plus interest in approximately one (1) year.

 

Various other holders of Convertible Promissory Notes agreed to convert their notes for an aggregate of 806,015 shares of common stock prior to the Exchange. As a result of these transactions, no convertible promissory notes remain outstanding, except for those convertible notes subject to revival if the Company fails to make payments pursuant to the Note Satisfaction Agreements. 

 

NOTE 3 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and incurring startup costs and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the period ended March 31, 2019 of $9,285,480. In addition, the Company’s development activities since inception have been financially sustained through equity financing. Management plans to seek funding through debt and equity financing and has recently acquired a new company as a wholly owned subsidiary.

 

 -11-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 4 – RELATED PARTY

 

For the three months ended March 31, 2019 and 2018, the Company had expenses totaling $13,320 and $56,500, respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying statement of operations. As of March 31, 2019, there was $0 in accounts payable – related party. As of March 31, 2019, there was convertible debt of $61,876 and accrued interest payable of $1,856 due to an officer and director.

 

NOTE 5 – CONVERTIBLE DEBT – RELATED PARTY

 

As of March 31, 2019, the Company had the following:

 

 Unsecured convertible debt, due 04/13/20, 4% interest, converts at a 30% discount to market price based on the last 20 days trading price     61,876  
Unsecured convertible debt, due 04/13/20, 4% interest, converts at $0.03 for a total of 873,334 shares     25,000  
Unsecured debt with shareholders of the Company, due 02/04/2020, 4% interest, interest due quarterly, converts at $0.03 for a total of 2,782,440 shares     79,667  
         
TOTAL   $ 166,543  

 

As of March 31, 2019, the Company has an outstanding total of $2,519 in accrued interest for the above convertible notes.

 

Below represent the Black-Scholes Option Pricing Model calculations for the above convertible note payables:

 

Payee   Number of options valued   Value of Convertible Option
Unsecured Convertible debt #1     4,335,523     $ 215,464  
Unsecured Convertible debt #2     838,611     $ 41,560  
Unsecured Convertible debt #3     2,672,374     $ 132,439  

 

NOTE 6 – NOTES PAYABLE

 

As of March 31, 2019, the Company had the following:

 

Unsecured debt with shareholders of the Company, due 01/17/2024, 4% interest.   $ 1,050,000  
Unsecured debt with shareholders of the Company, no due date, 0% interest,     700  
Less: Discount     —    
TOTAL   $ 1,050,700  

 

As of March 31, 2019, the Company has an outstanding total of $444,000 in accrued interest for the above note and past obligations which are unpaid.

 

 -12-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 7 – CONVERTIBLE DEBT

 

As of March 31, 2019, the Company had the following:

 

Unsecured convertible debt, due 11/01/18, 12% interest, converts at a 50% discount to market price based on the last 25 days trading price     110,000  
Unsecured convertible debt, due 02/02/19, 8% interest, converts at a 55% discount to market price based on the last 20 days trading price     50,000  
Unsecured convertible debt, due 01/19/17, 8% interest, default interest at 18%, converts at a 54% discount to market price based on the lowest trading prices in the last 20 days trading price     6,750  
         
SUBTOTAL     166,750  
Less: Discount     —    
TOTAL   $ 166,750  

 

Below represent the Black-Scholes Option Pricing Model calculations for the above convertible note payables:

 

Payee   Number of options valued   Value of Convertible Option
Unsecured Convertible debt #1     5,620,067     $ 276,466  
Unsecured Convertible debt #2     2,016,604     $ 99,118  
Unsecured Convertible debt #3     297,635     $ 7,010  

 

As of March 31, 2019, the Company has an outstanding total of $33,457 in accrued interest for the above convertible notes.

 

One of the convertible promissory notes is in default but management has not been able to make contact with this party, due to them living out of the country. We have calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock.

 

The Company has determined that the conversion feature embedded in the notes referred to above that contain a potential variable conversion amount constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt.

 

 -13-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 8 – STOCKHOLDERS’ EQUITY

 

Authorized Stock 

 

The Company has authorized 75,000,000 common shares with a par value of $0.001 per share.  Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000. Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000. During April 2018, the Company increased its authorized number of common shares to 2,500,000,000. The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval.

 

The shareholders of the Company approved a reverse stock split at a ratio of between 1-for-100 and 1-for 250. The Company received approval from FINRA for a reverse stock split of 1-for-250, which was effective as of July 23, 2018.

 

On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of our common stock equal to 0.00006% of our outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert.

 

As of March 31, 2019, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019. See recent developments for details.

 

Common Share Issuances

 

During the three months ended March 31, 2019, the Company issued a total of 1,802,067 shares of common stock for the conversion of debt totaling $270,300 including interest of $31,774.

 

Warrant Issuances

 

As of March 31, 2019, there were 16,800 warrants outstanding, of which 4,800 warrants are fully vested.

 

Adjustment to Additional Paid in Capital (APIC)

 

On January 1, 2019, the Company made an adjustment to APIC of $149,699.40 due to preferred stock conversions back in 2017 and 2018.

 

 -14-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 8 – STOCKHOLDERS’ EQUITY (CONTINUED)

 

Stock Issued for Services

 

On January 28, 2019, the Company entered into a marketing and sales consulting agreement with an individual for a period of six months. The Company issued 350,000 shares of common stock as the compensation for this agreement.

 

Share Conversion Agreements

 

All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares.

 

NOTE 9 – ACQUISITIONS

 

Acquisition of BergaMet and the Share Exchange Agreement

 

On February 4, 2019, the Company entered into a Share Exchange Agreement with BergaMet NA, LLC, a Delaware limited liability company (“BergaMet”), and the members of BergaMet, whereby the Company issued and exchanged 97,409,678 shares of its common stock for all of the outstanding equity securities of BergaMet (the “Exchange”). Through the Exchange, BergaMet became a wholly-owned subsidiary of the Company. The shares of common stock issued in the Exchange were equal to 80.1% of the Company’s outstanding common stock (post-exchange).

 

The assets acquired and liabilities assumed as part of our acquisition were recognized at their fair values as of the effective acquisition date, February 4, 2019. The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.

 

Cash   $ 437,826  
Current assets     2,801,317  
Current liabilities     (1,484,210 )
Net assets acquired   $ 1,754,934  

 

The purchase price method was used when calculating the fair market value of the BergaMet purchase. On February 4, 2019 the closing stock price for GRCK was $0.02. The total number of shares exchanged multiplied by the closing stock price equaled a purchase value of $1,948,194. The difference between the net assets acquired and the purchase value was recorded as $193,260 of goodwill for the purchase. The Company viewed BergaMet’s balance sheet as being fairly valued as of February 4, 2019 so no adjustment was needed under the purchase price method of valuation.

 

 -15-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 10 – DISCONTINUED OPERATIONS

 

Healthy Extracts

 

On January 1, 2019, the Company decided to discontinue operating the Healthy Extracts division. This division did not have any operations in 2019. Due to the closure, the company wrote off the two inter-company loans totaling $714, the common stock and APIC held from the purchase totaling $52,071, and retained earnings of $52,071 in the 1st quarter of 2019.

 

NOTE 11 – BUSINESS SEGMENT INFORMATION

 

As of March 31, 2019, the Company operated in three reportable segments (Corporate, CBD, Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the three months ended March 31, 2019.

 

    CONSOLIDATED   HEALTH SUPPLEMENTS   CBD   CORPORATE
Revenue     97,273       97,273       —         —    
Cost of Revenue     31,763       31,263       500       —    
Long-lived Assets     —         —         —         —    
Loss Before Income Tax     1,727,419       (113,543 )     92,771       1,748,905  
Identifiable Assets     2,925,991       2,716,483       162       209,345  
Depreciation and Amortization     1,614       1,383       —         231  

 

 -16-

GREY CLOAK TECH INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019 and 2018

 

NOTE 12 – SUBSEQUENT EVENTS

 

Note Conversion Agreements and Advance Conversion Agreements

 

Effective April 13, 2020, we entered into a total of eighteen (18) agreements (16) Note Conversion Agreements and 2 Advance Conversion Agreements) whereby an aggregate of $1,508,407.84 in outstanding principal and accrued interest was converted into an aggregate of 39,248,714 shares of our common stock. The conversion price was either $0.03 per share or $0.05 per share, depending on the individual agreement. The conversions included notes and advances held by our officers and directors and our largest shareholder, as follows:

 

Name   Aggregate Principal and Interest   Aggregate Shares
Jay W. Decker   $ 1,282,231.11       33,418,004  
William Bossung   $ 65,677.84       2,189,262  
First Capital Properties LLC   $ 16,180.00       539,334  
Shelton S. Decker   $ 33,717.78       782,223  
Logan B. Decker   $ 33,717.78       782,223  
Kevin Pitts   $ 51,255.56       1,025,112  
Innovation Group Holdings, LLC   $ 25,627.78       512,556  

 

Acquisition of Ultimate Brain Nutrients, LLC

 

On April 3, 2020, we entered into a Share Exchange Agreement by and among Grey Cloak Tech Inc., Ultimate Brain Nutrients, LLC, a Delaware limited liability company (“UBN”), and the members of UBN, whereby we issued and exchanged 90,000,960 shares of our common stock for all of the outstanding equity securities of UBN. UBN is now our wholly-owned subsidiary. The shares of common stock issued in the Exchange are equal to approximately 42.5% of our outstanding common stock immediately following the exchange.

 

COVID-19

 The COVID-19 outbreak in early 2020 has adversely affected, and may continue to adversely affect economic activity globally, nationally and locally. These economic and market conditions and other effects of the COVID-19 outbreak may adversely affect the Company. At this point, the extent to which COVID-19 may impact the Company's business is uncertain.

 

 -17-

ITEM 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

 

Although the forward-looking statements in this Quarterly Statement reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

The following discussion and analysis of financial condition and results of operations of the Company is based upon, and should be read in conjunction with, its unaudited financial statements and related notes elsewhere in this Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States.

 

Summary Overview

 

We were formed in December 2014. We had revenues of $67,131 in the year ended December 31, 2018 from a variety of sources. We had revenues of $97,273 in the three month period ended March 31, 2019. In March 2018, we discontinued our previous business to shift our focus solely to sales of our hemp oil and nutraceutical products.

 

Eqova Life Sciences

 

On October 17, 2017, we acquired Eqova Life Sciences, a Nevada corporation (“Eqova”), through an exchange of shares of our Series A Convertible Preferred Stock for all of the outstanding equity interest of Eqova. As part of the Exchange, we have brought on Eqova’s President and Director, Patrick Stiles, to serve as our President and Chief Executive Officer and as a Director on our Board of Directors.

 

 -18-

 Table of Contents

Eqova is a medically-focused CBD company that develops clinical grade full spectrum hemp oil products, sold exclusively via partnerships with licensed medical practitioners to use with their patients. To date, we know of no other hemp oil company exclusively focused on the practitioner market, leaving it largely underserved. According to The Hemp Business Journal, CBD products marketplace are projected to grow by 700% by 2020 with annual sales reaching $2.1 billion. With a head start in a growing marketplace, we believe that Eqova provides us with a prime growth opportunity with an established business. Revenues of our hemp oil products from the acquisition of Eqova for the year ended December 31, 2018 were $64,384 and for the three months ended March 31, 2019 and 2018 were $0 and $19,856, respectively.

 

BergaMet NA, LLC

 

On February 4, 2019, we issued and exchanged shares of our common stock for all of the outstanding equity securities of BergaMet.

 

Through the exchange, we were able to secure funds in BergaMet to pay off some debt and provide capital for operations. We paid an aggregate of $353,908 and are obligated to pay another $164,578 approximately one (1) year later to retire convertible debt. Currently, we are default on these obligations. Prior to the exchange, we also entered into agreements with other holders of convertible debt to convert their notes for an aggregate of 806,015 shares of common stock. We also entered into conversion agreements with the holders of our Series A Convertible Preferred Stock whereby all of the outstanding preferred stock was converted for an aggregate of 15,592,986 shares of common stock. The conversion and repayment of the preferred stock and convertible debt have greatly improved our capitalization structure.

 

The acquisition of BergaMet has been extremely beneficial to us. In addition to paying off our convertible debt, we are now able to better position ourselves in the market. BergaMet is an established company that was already generating revenues when we acquired it. BergaMet also has unique products that will fit nicely with our existing business. We now plan on expanding our product line to other nutraceuticals.

 

Going Concern

 

As a result of our financial condition, we have received a report from our independent registered public accounting firm for our financial statements for the years ended December 31, 2018 and 2017 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern. From inception (December 19, 2014) through the end of December 31, 2018, we have incurred accumulated net losses of $11,012,899. In order to continue as a going concern we must effectively balance many factors and generate more revenue so that we can fund our operations from our sales and revenues. If we are not able to do this we may not be able to continue as an operating company. At our current revenue and burn rate, our cash on hand will last less than one month, and thus we must raise capital by issuing debt or through the sale of our stock. However, there is no assurance that our existing cash flow will be adequate to satisfy our existing operating expenses and capital requirements.

 

 -19-

 Table of Contents

Results of Operations for the Three Months Ended March 31, 2019 and 2018

 

Introduction

 

We had revenues of $97,273 for the three months ended March 31, 2019, compared to $19,856 for the three months ended March 31, 2018, an increase of $77,417, or 390%. Our operating expenses were $262,516 for the three months ended March 31, 2019, compared to $232,064 for the three months ended March 31, 2018, an increase of $30,452, or 13%.

 

Our operating expenses consisted entirely of general and administrative expenses.

 

Revenues and Net Operating Loss

 

Our revenue, operating expenses, net operating loss, and net loss for the three months ended March 31, 2019 and 2018 were as follows:

 

    Three Months   Three Months    
    March 31,   March 31,   Increase/
    2019   2018   (Decrease)
             
Revenue   $ 97,273     $ 19,856     $ 77,417  
                         
Cost of Revenue     31,763       14,699       17,064  
                         
Operating expenses:                        
General and administrative     262,516       232,064       30,452  
Total operating expenses     262,516       232,064       30,452  
                         
Other income (expense)                        
Interest expenses, net of interest income     (12,864 )     (408,467 )     (395,603 )
Change in fair value on derivative     1,749,436       1,097,469       651,967  
Loss on extinguishment of debt     53,038       (526,481 )     579,519  
Total other income (expense)     1,789,611       162,521       1,627,090  
                         
Net income (loss)   $ 1,592,604     $ (64,386 )   $ 1,656,990  

 

Revenues

 

Revenues were $97,273 for the three months ended March 31, 2019, compared to $19,856 for the three months ended March 31, 2018, an increase of $77,417, or 390%. The increase supports the transition to our new business selling CBD products.

 

Cost of Revenue

 

Cost of revenue was $31,763 for the three months ended March 31, 2019, compared to $14,699 for the three months ended March 31, 2018, an increase of $17,064, or 116%. Gross profit was $65,509 for the three months ended March 31, 2019, compared to $5,157 for the three months ended March 31, 2018, an increase of $60,352, or 1170%.

 

 -20-

 Table of Contents

General and Administrative

 

General and administrative expenses were $262,516 for the three months ended March 31, 2019, compared to $232,064 for the three months ended March 31, 2018. In the three months ended March 31, 2019, general and administrative expenses consisted mainly of professional fees $95,598, consulting fees $66,754, salary and wages $31,118, postage $12,882, advertising $11,629, and transfer agent and filing fees $4,687. In the three months ended March 31, 2018, general and administrative expense consisted mainly of compensation to our management of $82,248, consulting of $3,893, selling expenses of $1,777, commissions of $2,917, transfer agent and filing fees of $929, and professional fees of $30,384.

 

Other Income (Expense)

 

Other income was $1,789,611 for the three months ended March 31, 2019, compared to $162,521 for the three months ended March 31, 2018, an increase of $1,627,090, or 1001%. Other income (expense) consisted of interest expense, net of interest income of $(12,864), change in fair value on derivative of $1,749,436, and loss on extinguishment of debt of $53,038. Other income (expense) for the three months ended March 31, 2018 consisted primarily of a change in the fair value on derivatives of $1,097,469, offset by interest expense, net of interest income of $(408,467) and loss on extinguishment of debt of (526,481).

 

Net Income (Loss)

 

Net income (loss) was $1,592,604, or $0.02 per share, for the three months ended March 31, 2019, compared to $(64,386), or $0.00 per share, for the three months ended March 31, 2018, an increase of $1,656,990. Net income increased primarily because of a change in fair value on derivative.

 

Liquidity and Capital Resources

 

Introduction

 

During the three months ended March 31, 2019, we were unable to generate sufficient revenues and had negative operating cash flows. Our cash on hand as of December 31, 2018 was $485, and as of March 31, 2019 was $339,650. The increase in cash on hand was primarily from the purchase of BergaMet and proceeds from the issuance of notes payable. Our monthly cash flow burn rate for 2018 was approximately $27,400, and for the three months ended March 31, 2019 it was approximately $721,000. We have strong short and medium term cash needs. We anticipate that these needs will be satisfied through increased revenues and the issuance of debt or the sale of our securities until such time as our cash flows from operations will satisfy our cash flow needs.

 

Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2019 and December 31, 2018, respectively, are as follows:

 

    March 31   December 31,   Increase/
    2019   2018   (Decrease)
             
Cash   $ 339,650     $ 485     $ 339,165  
Total Current Assets     2,710,635       85,042       2,625,593  
Total Assets     2,925,991       85,768       2,840,223  
Total Current and Total Liabilities     2,682,073       3,649,984       (967,911 )

 

 -21-

 Table of Contents

Our cash increased because, upon the acquisition of BergaMet, we were able to access their cash, and we issued notes payable to raise cash. Our total current assets and total assets increased for the same reason, including inventory in the amount of $2,343,828 as of March 31, 2019 that was owned by BergaMet. Our total current and total liabilities decreased during the three months ended March 31, 2018 primarily because we were able to shed over $1,000,000 of notes payable during the BergaMet acquisition. Our accumulated deficit decreased during the three months ended March 31, 2018 by $1,594,980 to $9,417,919 while our total stockholders’ equity increased by $2,840,223.

 

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

 

Cash Requirements

 

Our cash on hand as of March 31, 2018 was $339,650. Based on our current level of revenues and monthly burn rate of approximately $721,000 per month, we will need to continue to fund operations by raising capital from the sale of our stock and debt financings.

 

Sources and Uses of Cash

 

Operating Activities

 

We had net cash used in operating activities of $2,167,128 for the three months ended March 31, 2019, compared to $188,184 for the three months ended March 31, 2018. We use our cash for normal business operations.

 

Investing Activities

 

We had $1,963,321 cash flows provided by investing activities for the three months ended March 31, 2019, compared to zero for the three months ended March 31, 2018. The increase was primarily because of cash from the acquisition of BergaMet.

 

Financing Activities

 

Our net cash provided by financing activities for the three months ended March 31, 2019 was $542,971, compared to $194,583 for the three months ended March 31, 2018. The increase of $348,388 was primarily because of the proceeds of notes payable, offset in party by repayments of notes payable.

 

 -22-

 Table of Contents

ITEM 3 Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

ITEM 4 Controls and Procedures

 

(a)       Disclosure Controls and Procedures

 

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of March 31, 2019, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2019, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in our Annual Report on Internal Control Over Financial Reporting filed in our Annual Report on Form 10-K.

 

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all errors and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

(b)       Changes in Internal Control over Financial Reporting

 

No change in our system of internal control over financial reporting occurred during the period covered by this report, the three month period ended March 31, 2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 -23-

 Table of Contents

PART II – OTHER INFORMATION

 

ITEM 1 Legal Proceedings

 

We are not a party to or otherwise involved in any legal proceedings.

 

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

 

ITEM 1A Risk Factors

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

 

Note Conversions

 

In January 2019, we issued an aggregate of 996,052 shares of our common stock, restricted in accordance with Rule 144, to two noteholders upon the partial conversion of promissory notes.

 

Acquisition of BergaMet and the Share Exchange Agreement

 

On February 4, 2019, we entered into a Share Exchange Agreement by and among the Company, BergaMet NA, LLC, a Delaware limited liability company (“BergaMet”), and the members of BergaMet, whereby we issued and exchanged 97,409,678 shares of our common stock, restricted in accordance with Rule 144, for all of the outstanding equity securities of BergaMet.

 

Note Satisfaction Agreements

 

Prior to the Exchange described above, various holders of Convertible Promissory Notes agreed to convert their notes for an aggregate of 806,015 shares of common stock, restricted in accordance with Rule 144, prior to the Exchange.

 

Share Conversion Agreements

 

All of the holders of our Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange described above. As a result, no shares of our Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock, restricted in accordance with Rule 144, were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of our common stock.

 

 -24-

 Table of Contents

Services

 

In February 2019, we issued 350,000 shares of our common stock, restricted in accordance with Rule 144, to one individual for services rendered.

 

All of the issuances of securities above were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, the investors were sophisticated and familiar with our operations, and there was no solicitation in connection with the offering.

 

ITEM 3 Defaults Upon Senior Securities

 

There have been no events which are required to be reported under this Item.

 

ITEM 4 Mine Safety Disclosures

 

Not applicable.

 

ITEM 5 Other Information

 

None.

 

 -25-

 Table of Contents

ITEM 6 Exhibits

 

(a)       Exhibits

 

Exhibit Number   Name and/or Identification of Exhibit
     
10.1   Share Exchange Agreement dated February 4, 2019 entered into with BergaMet NA, LLC and its members
     
10.2   Form of Note Satisfaction Agreement
     
10.3   Form of Preferred Stock Conversion Agreement
     
31.1   Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
     
31.2   Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
     
32.1   Chief Executive Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Chief Financial Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
100.INS   XBRL Instance Document
     
100.SCH   XBRL Schema Document
     
100.CAL   XBRL Calculation Linkbase Document
     
100.DEF   XBRL Definition Linkbase Document
     
100.LAB   XBRL Labels Linkbase Document
     
100.PRE   XBRL Presentation Linkbase Document

 

 -26-

 Table of Contents

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  Grey Cloak Tech Inc.
   
   
Dated:  May 28, 2020 /s/ Kevin Pitts
  By: Kevin “Duke” Pitts
  Its: President

 

 -27-

SHARE EXCHANGE AGREEMENT

 

dated as of

 

February 4, 2019

 

by and among

 

Grey Cloak Tech Inc.,

a Nevada corporation (“GCT”),

 

BergaMet NA, LLC,

a Delaware limited liability company (“BergaMet”),

 

and

 

The Members of BergaMet

   

 
 

SHARE EXCHANGE AGREEMENT

 

This Share Exchange Agreement (this “Agreement”) is entered into on February 4, 2019 (the “Effective Date”) and is by and among Grey Cloak Tech Inc., a Nevada corporation (“GCT”), on the one hand, and BergaMet NA, LLC, a Delaware limited liability company (“BergaMet”), and the members of BergaMet as listed on Exhibit A (each a “BergaMet Member” and collectively the “BergaMet Members”), on the other hand. Each of GCT, BergaMet, and the BergaMet Members may be referred to herein as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, BergaMet is engaged in the business of developing, manufacturing, promoting, selling and distributing nutritional supplement products that include citrus bergamot (the “Business”);

 

WHEREAS, the BergaMet Members are the beneficial and record owners of all of the issued and outstanding equity interests of BergaMet;

 

WHEREAS, the BergaMet Members desire to aquire from GCT, and GCT desires to issue to the BergaMet Members, shares of GCT common stock constituting 80% of all of GCT’s issued and outstanding capital stock immediately following the Closing in exchange for all of the issued and outstanding equity interests of BergaMet (the “Exchange”);

 

WHEREAS, it is the intention of the Parties that upon Closing BergaMet shall become a wholly-owned subsidiary of GCT; and

 

WHEREAS, the Parties intend that the Exchange, as set forth in this Agreement, shall qualify as a tax-free transfer under the provisions of Section 351 of the Internal Revenue Code, as amended (the “Code”).

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE I
THE EXCHANGE

 

1.1              The Exchange of GCT Shares for BergaMet Units.

 

(a)               At the Closing (as defined in Section 1.2) and subject to the terms and conditions set forth herein, each BergaMet Member shall purchase, and GCT shall issue and sell to each BergaMet Member, 2,140.872 shares of GCT’s common stock for each BergaMet Unit held by the BergaMet Member (the “Exchange Ratio”). Such shares of GCT’s common stock shall collectively (i) be referred to as the “Exchange Shares”, (ii) constitute 97,409,678 shares of GCT’s common stock in total, and (iii) constitute 80.1% of the issued and outstanding capital stock of GCT immediately following the Closing (after taking into account the conversions to common stock of any and all of convertible notes and preferred stock, which are contemplated by this Agreement to occur at or prior the Closing).

 

Page 1 of 30

(b)               At the Closing and subject to the terms and conditions set forth herein, as consideration for the BergaMet Member’s Exchange Shares, each BergaMet Member shall contribute, sell, convey, assign, and transfer to GCT, and GCT shall purchase, acquire and accept from the BergaMet Member, all of the equity interests of BergaMet. Such equity interests of BergaMet shall generally be referred to as the “BergaMet Units”, and shall in the aggregate (i) be comprised of 45,500 Class A Units and (ii) constitute all of the issued and outstanding equity interests of BergaMet.

 

(c)               GCT shall issue the Exchange Shares to the BergaMet Members by delivering (within the time frame set forth in Section 1.3(b)(ii) hereof) a stock certificate to each BergaMet Member registered in the name of the BergaMet Member, or the BergaMet Member’s nominees, evidencing the Exchange Shares (the “Exchange Shares Certificates”).

 

(d)               For federal income tax purposes, the Exchange is intended to constitute a tax-free transfer within the meaning of Section 351 of the Code, and the Parties shall report the transactions contemplated by this Agreement consistent with such intent and shall take no position in any tax filing or legal proceeding inconsistent therewith.

 

1.2              Closing. Unless this Agreement shall have been terminated and the transactions herein contemplated shall have been abandoned pursuant to Article V and subject to the satisfaction or waiver of the conditions set forth in Article IV, the closing of the Exchange (the “Closing”) will take place at 5:00 p.m. Pacific Time on the Effective Date. The Closing shall take place at the offices of GCT, unless another date, time, or place is agreed to in writing by GCT and BergaMet.

 

1.3              Deliveries at Closing.

 

(a)               At the Closing, BergaMet must execute and deliver:

 

(i)                 to GCT and each BergaMet Member, a counterpart signature page, executed by BergaMet, to each Joinder Agreement, the form of which is attached hereto as Exhibit D (each “Joinder Agreement”), that has been executed by such BergaMet Member;

(ii)              to GCT, a certificate, dated as of the Effective Date, executed by a manager or an executive officer of BergaMet, in the form attached hereto as Exhibit B(the “BergaMet Representation Certificate”), stating that each of the conditions set forth in Section 4.2, with respect to BergaMet, have been satisfied; and

Page 2 of 30

(iii)            to GCT, a certificate, dated as of the Effective Date, executed by a manager or an executive officer of BergaMet in the form attached hereto as Exhibit C (the “BergaMet Officer’s Certificate”), certifying as to the full force and effect of, and attaching as exhibits to such certificate, (A) the organizational documents of BergaMet; (B) a certificate of good standing, dated as of a date within five (5) days of the Effective Date, from the Secretary of State of the State of Delaware; (C) resolutions of BergaMet’s manager approving the Agreement and the transactions contemplated herein; and (D) resolutions of the BergaMet Members approving the Agreement and the transactions contemplated herein.

(b)               At the Closing (unless otherwise indicated) GCT must execute and deliver:

 

(i)                 to BergaMet and each BergaMet Member, a counterpart signature page, executed by GCT, to each Joinder Agreement that has been executed by such BergaMet Member;

(ii)              within ten (10) business days of the Effective Date, to the BergaMet Members, the Exchange Shares Certificates;

(iii)            to the BergaMet Members and BergaMet, a certificate dated as of the Effective Date, executed by an executive officer of GCT, in the form attached hereto as Exhibit E (the “GCT Representation Certificate”), stating that each of the conditions in Section 4.3 have been satisfied;

(iv)             to the BergaMet Members and BergaMet, a certificate, dated as of the Effective Date, executed by an executive officer of GCT in the form attached hereto as Exhibit F (the “GCT Officer’s Certificate”), certifying as to the full force and effect of, and attaching as exhibits to such certificate, (A) the organizational documents of GCT; (B) a certificate of good standing, dated as of a date within five (5) days of the Effective Date, from the Secretary of State of the State of Nevada; and (C) resolutions of GCT’s Board of Directors approving the Agreement and the transactions contemplated herein, including the appointments set forth in Section 1.4;

(v)               to Bill Bossung, a promissory note in the principal amount of $61,875.91, in a form acceptable to Bergamet (the “Bossung Note”), with respect to amounts previously advanced to GCT by Bill Bossung (the “Bossung Advance”);

(vi)             to Genuine Partners, a promissory note in the principal amount of $79,666.67, in a form acceptable to Bergamet (the “Genuine Partners Note” and together with the Bossung Note, the “Bossung/Genuine Partners Notes”), with respect to amounts previously advanced to GCT by Tim Brasel and/or Genuine Partners (the “Genuine Partners Advance”, and together with the Bossung Advance, the “Bossung/Genuine Partners Advances”); and

Page 3 of 30

(vii)          to Jay W. Decker, an assumption of Bergamet’s obligations under a promissory note issued by BergaMet to Jay W. Decker in the principal amount of $1,050,000 (the “Decker Note”), in a form acceptable to Bergamet, with respect to amounts previously advanced to BergaMet by Jay W. Decker (the “Decker Advance”).

1.4              Directors and Executives of GCT. Effective at Closing, the parties identified on Exhibit G shall be appointed to GCT’s Board of Directors or as executive officers as indicated.

 

ARTICLE II
REPRESENTATIONS AND WARRANTIES

 

2.1              Representations and Warranties of BergaMet. BergaMet represents and warrants to GCT as follows as of the Effective Date:

 

(a)               Organization, Standing, and Power. BergaMet is duly organized, validly existing, and in good standing under the laws of the State of Delaware and has the requisite power and authority and all government licenses, authorizations, permits, consents, and approvals required to own, lease, and operate its properties and carry on its business as now being conducted. BergaMet is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect (as defined in Section 7.2) with respect to BergaMet.

 

(b)               Subsidiaries. BergaMet does not own directly or indirectly, any equity or other ownership interest in any company, corporation, partnership, joint venture, or otherwise.

 

(c)               Capital Structure. BergaMet has 45,500 Class A Units issued and outstanding. No other equity securities of BergaMet are issued, reserved for issuance, or outstanding. All issued and outstanding equity interests of BergaMet are nonassessable and not subject to preemptive rights. There are no outstanding bonds, debentures, notes, or other indebtedness, or other securities of BergaMet having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters. There are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements, or undertakings of any kind to which BergaMet is a party or by which they are bound obligating BergaMet to issue, deliver or sell, or cause to be issued, delivered or sold, additional membership interests or other equity or voting securities of BergaMet or obligating BergaMet to issue, grant, extend, or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement, or undertaking. There are no outstanding contractual obligations, commitments, understandings, or arrangements of BergaMet to repurchase, redeem, or otherwise acquire or make any payment in respect of any membership interest of BergaMet. There are no agreements or arrangements pursuant to which BergaMet is or could be required to register Bergamet’s equity interests or other securities under the Securities Act of 1933, as amended and the rules and regulations promulgated thereunder (the “Securities Act”) or other agreements or arrangements with or among any security holders of Bergamet with respect to securities of BergaMet.

 

Page 4 of 30

(d)               Company Authorization. As of the Closing, BergaMet has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by BergaMet and the consummation by BergaMet of the transactions contemplated hereby have been (or at Closing will have been) duly authorized by all necessary action on the part of BergaMet. This Agreement has been duly executed and when delivered by BergaMet shall constitute a valid and binding obligation of BergaMet, enforceable against BergaMet in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

 

(e)               Non-Contravention. The execution and delivery of this Agreement do not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to a loss of a material benefit under, or result in the creation of any lien upon any of the properties or assets of BergaMet under, (i) BergaMet’s certificate of formation, limited liability company agreement or other organizational or charter documents of BergaMet; (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise or license applicable to BergaMet, its properties or assets (other than any consent of H&AD S.r.l., an Italian corporation (“H&AD”), required with respect to BergaMet’s rights under the Purchase & Supply Agreement dated January 1, 2015 originally executed by DOJS Holding Pty Ltd and H&AD (the “Supply Agreement”)); or (iii) subject to the governmental filings and other matters referred to in the following sentence, any judgment, order, decree, statute, law, ordinance, rule, regulation or arbitration award applicable to BergaMet, its properties or assets, other than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, defaults, rights, losses, or liens that individually or in the aggregate could not have a Material Adverse Effect with respect to BergaMet or could not prevent, hinder or materially delay the ability of BergaMet to consummate the transactions contemplated by this Agreement.

 

(f)                Governmental Authorization. No consent, approval, order, or authorization of, or registration, declaration or filing with, or notice to, any United States court, administrative agency or commission, or other federal, state, or local government or other governmental authority, agency, domestic or foreign (a “Governmental Entity”), is required by or with respect to BergaMet in connection with the execution and delivery of this Agreement by BergaMet or the

Page 5 of 30

consummation by BergaMet of the transactions contemplated hereby, except, with respect to this Agreement, any filings under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

(g)               Financial Statements. BergaMet has previously delivered to GCT BergaMet-prepared financial statements of BergaMet consisting of the balance sheet of BergaMet as of December 31, 2018, and the related statement of income for the year then ended (“Financial Statements”). The Financial Statements have been prepared in accordance with GAAP and are complete and correct and have been prepared from and substantially conform with the books and records of the Business and present fairly the financial condition and results of operations of the Business as of the dates and for the periods indicated in all material respects.

(h)               Absence of Certain Changes or Events. Since December 31, 2018, there has not been any (i) a Material Adverse Effect with respect to BergaMet (which expressly excludes amounts paid or incurred by BergaMet under the Supply Agreement), or (ii) any event or occurrence that would reasonably be expected to prevent the ability of BergaMet to consummate the transactions contemplated by this Agreement.

(i)                 Legal Proceedings. There are no legal proceedings pending or, to BergaMet’s Knowledge, threatened against or by BergaMet (a) relating to or affecting the Business; or (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement; and no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action. There are no outstanding and no unsatisfied judgments, penalties, or awards against, relating to or affecting the Business.

(j)                 Compliance with Laws. To BergaMet’s Knowledge, the conduct of the Business complies with all statutes, laws, regulations ordinances, rules, judgments, orders, decrees or arbitration awards applicable to BergaMet.

(k)               Taxes. All Tax Returns with respect to the Business required to be filed by BergaMet for any period prior to Closing have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. All Taxes due and owing by BergaMet (whether or not shown on any Tax Return) have been, or will be, timely paid. Any deficiencies asserted, or assessments made, against BergaMet as a result of any examinations by any taxing authority have been fully paid. BergaMet is not a party to any Action by any taxing authority. There are no pending or, to BergaMet’s Knowledge, threatened Actions by any taxing authority. There are no Encumbrances for Taxes upon any of BergaMet’s assets nor, to BergaMet’s Knowledge, is any taxing authority in the process of imposing any Encumbrances for Taxes on any of BergaMet’s assets (other than for current Taxes not yet due and payable).

(l)                 Guaranties. BergaMet has not guaranteed any dividend, obligation, or indebtedness of any person.

Page 6 of 30

(m)             Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by BergaMet to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by this Agreement.

(n)               Acknowledgement of GCT’s Business. BergaMet acknowledges and understands that GCT operates in the cannabis industry, specifically as it relates to full spectrum hemp oil, and that GCT’s products contain CBD and trace amounts of THC, and any change in current federal or state statutes, regulation or enforcement, or current federal or state statutes, regulation or enforcement may have a Material Adverse Effect on the business of GCT.

 

2.2              Representations and Warranties of GCT. GCT represents and warrants to BergaMet and the BergaMet Members as follows as of the Effective Date and as of the Closing:

 

(a)               Organization, Standing and Power. GCT is duly organized, validly existing and in good standing under the laws of the State of Nevada and has the requisite corporate power and authority and all government licenses, authorizations, permits, consents, and approvals required to own, lease and operate its properties and carry on its business as now being conducted. GCT is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect with respect to GCT.

 

(b)               Subsidiaries. GCT has one wholly-owned subsidiary, Eqova Life Sciences, a Nevada corporation (the “Subsidiary”), and does not otherwise own directly or indirectly, any equity or other ownership interest in any company, corporation, partnership, joint venture, or otherwise. For purposes of Section 2.2(h) through Section 2.2(s), references to GCT shall be deemed to include the Subsidiary.

 

(c)               Capital Structure of GCT.

 

(i)                 The Exchange Shares will be, when issued, duly authorized, validly issued, fully paid and nonassessable, not subject to preemptive rights, and issued in compliance with all applicable state and federal laws concerning the issuance of securities. The Exchange Shares constitute 80% of the issued and outstanding capital stock of GCT immediately following the Closing (after taking into account the conversions to common stock of any and all of convertible notes and preferred stock, which are contemplated by this Agreement to occur at or prior the Closing). Immediately following the Closing, the capitalization of GCT and ownership thereof will be as set forth in Exhibit H. Except as set forth in Exhibit H, no shares of capital stock or other equity securities of GCT are or will be issued, reserved for issuance or outstanding. All issued and outstanding shares of capital stock of GCT are or will be fully paid and nonassessable

Page 7 of 30

and not subject to preemptive rights. Immediately following the Closing, there will be no outstanding bonds, debentures, notes, or other indebtedness or other securities of GCT having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters. Immediately following the Closing, there will be no outstanding securities, warrants, calls, rights, commitments, agreements, arrangements, or undertakings of any kind to which GCT is a party or by which they are bound, obligating GCT to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity or voting securities of GCT. Immediately following the Closing, there will be no outstanding contractual obligations, commitments, understandings, or arrangements of GCT to repurchase, redeem, or otherwise acquire or make any payment in respect of any shares of capital stock of GCT.

(ii)              Only Common Stock Outstanding. Immediately following the Closing, there will be no outstanding shares of GCT’s Series A Convertible Preferred Stock, convertible notes, warrants or any other securities, instruments or rights convertible or exercisable into capital stock of GCT. Immediately following the Closing, shares of GCT’s common stock will be the only class or series of GCT’s capital stock (A) issued and outstanding and (B) authorized for issuance by GCT. Without limiting the generality of the foregoing, as of immediately following the Closing:

1)                  No Series A Convertible Preferred Stock. All holders of GCT’s outstanding Series A Convertible Preferred Stock have converted their shares into GCT common stock.

2)                  Convertible Notes. All convertible notes previously issued by GCT and outstanding immediately prior to Closing have been, or are subject to agreements with GCT for such convertible notes to be, at or prior to the Closing, (A) paid and discharged in full at Closing (such payoffs, the “Closing Note Payoffs”), for which the aggregate payoff does not exceed $353,907.97; (B) converted into GCT capital stock prior to the Closing; (C) amended to be a nonconvertible note on terms and in a form satisfactory to BergaMet (the “Restated-as-Nonconvertible Note”) for which the balance owing at Closing does not exceed $110,000.00; and/or (D) amended on terms satisfactory to BergaMet for a suspension conversion rights that expires after one year if the balance is then unpaid (the “Amended-and-Deferred Note”) for which the balance owing at Closing does not exceed $54,578.00; provided however a single convertible note, for which the note holder cannot be located and for which the balance owing at Closing does not exceed $6,749.69, plus interest, may continue to remain outstanding at and following the Closing. A complete and accurate written summary of all Closing Note Payoffs, the Restated-as-Convertible Note and the Amended-and-Deferred Note is attached as Section 2.2(c) of the Disclosure Schedules.

3)                  No Warrants. There are no outstanding stock purchase warrants or other similar rights to acquire capital stock of GCT, other than an aggregate of 42,800 warrants previously disclosed to BergaMet, each with an exercise price of at least $30.00 per share.

Page 8 of 30

Each such other warrant or right previously issued by GCT has either been (A) cancelled or (B) exercised prior to the Closing.

As of the Closing, the Company has valid and binding agreements with third parties to ensure that the foregoing will be true and correct immediately following the Closing.

(d)               Corporate Authority. GCT has all requisite corporate and other power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by GCT and the consummation by GCT of the transactions contemplated hereby have been (or at Closing will have been) duly authorized by all necessary corporate action on the part of GCT. This Agreement has been duly executed and when delivered by GCT shall constitute a valid and binding obligation of GCT, enforceable against GCT in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency, or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

 

(e)               Non-Contravention. The execution and delivery of this Agreement do not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to loss of a material benefit under, or result in the creation of any lien upon any of the properties or assets of GCT under, (i) its articles of incorporation, bylaws, or other charter documents of GCT; (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, or license applicable to GCT, its properties or assets; or (iii) subject to the governmental filings and other matters referred to in the following sentence, any judgment, order, decree, statute, law, ordinance, rule, regulation, or arbitration award applicable to GCT, its properties or assets, other than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, defaults, rights, losses, or liens that individually or in the aggregate could not have a Material Adverse Effect with respect to GCT or could not prevent, hinder or materially delay the ability of GCT to consummate the transactions contemplated by this Agreement.

 

(f)                Government Authorization. No consent, approval, order or authorization of, or registration, declaration, or filing with, or notice to, any Governmental Entity, is required by or with respect to GCT in connection with the execution and delivery of this Agreement by GCT, or the consummation by GCT of the transactions contemplated hereby, except, with respect to this Agreement, any filings under the Securities Act or the Exchange Act.

 

(g)               Financial Statements. GCT has previously delivered to BergaMet GCT’s financial statements consisting of the audited balance sheet of GCT’s business operations as of December 31, 2017 and 2016 and the related statements of income and cash flows for the years then ended, and the unaudited balance sheet of GCT’s business operations as of September 30,

Page 9 of 30

2018 and the related statements of income and cash flows for the nine (9) month period then ended (the “GCT’s Financial Statements”). GCT’s Financial Statements have been prepared in accordance with GAAP and are complete and correct and have been prepared from and substantially conform with the books and records of GCT and present fairly the financial condition and results of GCT’s business operations as of the dates and for the periods indicated.

(h)               Undisclosed Liabilities. GCT has no liabilities, whether known or unknown, whether absolute or contingent, whether liquidated or unliquidated and whether due or to become due (“Liabilities”), except (a) the Bossung/Genuine Partners Advances (and the obligation to assume the Decker Note at the Closing); (b) the Restated-as-Nonconvertible Notes; (c) the Closing Note Payoffs; and (d) other payment obligations (including without limitations all legal fees and costs, accounting fees and other third party charges incurred in connection with this Agreement and the transactions contemplated hereby for services performed through the Closing) that do not exceed $53,200 in the aggregate.

(i)                 Absence of Certain Changes, Events, and Conditions. Since September 30, 2018, and except as listed on Section 2.2(i) of the Disclosure Schedules, none of the following has occurred, except that which would not have a Material Adverse Effect:

(i)                 material change in any method of accounting or accounting practice for the Business;

(ii)              entry into any GCT Contract;

(iii)            incurrence, assumption, or guarantee of any indebtedness for borrowed money in connection with GCT’s business operations;

(iv)             transfer, assignment, sale, lien, or other disposition of any of GCT’s assets except in the ordinary course of business;

(v)               cancellation of any debts or claims or amendment, termination, or waiver of any rights of GCT;

(vi)             transfer, assignment, or grant of any license or sublicense of any material rights under or with respect to any of the Intellectual Property;

(vii)          material damage, destruction or loss, or any material interruption in use, of any of GCT’s assets, whether or not covered by insurance;

(viii)        grant of any bonuses, whether monetary or otherwise, or any general wage or salary increases in respect of any employees, other than as provided for in any written agreements or consistent with past practice, or change in the terms of employment for any employee;

Page 10 of 30

(ix)             loan to, or entry into any other transaction with, any member, manager or employee of GCT; or

(x)               any Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.

(j)                 GCT Contracts. Except as reflected in the GCT Financial Statements or in filings by GCT with the Securities and Exchange Commission, there are no Contracts (i) by which any of GCT’s assets are bound or affected; or (ii) to which GCT is a party or by which it is bound in connection with GCT’s assets, excluding the contracts executed in association with this Agreement (any such Contracts listed in Section 2.2(j) of the Disclosure Schedules, the “GCT Contracts”). Any GCT Contract is valid and binding on GCT in accordance with its terms and is in full force and effect. None of GCT or, to GCT’s Knowledge, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any GCT Contract. No event or circumstance has occurred that, to GCT’s Knowledge, with notice or lapse of time or both, would constitute an event of default under any GCT Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each GCT Contract (including all modifications, amendments, and supplements thereto and waivers thereunder) have been provided to GCT. There are no disputes pending or, to GCT’s Knowledge, threatened under any GCT Contract.

(k)               Title to, and Sufficiency of, Assets.

(i)                 GCT owns good, marketable title to all of its assets, free and clear of any Encumbrance, title imperfection, or restriction of any kind whatsoever (whether accrued, absolute, contingent, or otherwise), except the Encumbrances reflected in the GCT Financial Statements or in filings by GCT with the Securities and Exchange Commission.

(ii)              GCT’s assets are sufficient for the continued conduct of its operations after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property, and assets necessary to conduct GCT’s business operations as currently conducted.

(iii)            The Inventories will be, at the Closing, no less than ninety percent (90%) of the average inventory value for the previous ninety (90) days, consist of a quality and quantity usable and salable in the ordinary course of business, except for obsolete, damaged, or slow-moving items that have been written-off or written-down to fair market value or for which adequate reserves have been established.

Page 11 of 30

(l)                 Intellectual Property.

(i)                 All required filings and fees related to the Intellectual Property Assets, the lack of which would have a Material Adverse Effect, have been timely filed with and paid to the relevant Governmental Entities and authorized registrars, and all registrations relating to the Intellectual Property Assets, the lack of which would have a Material Adverse Effect, are otherwise in good standing. GCT has provided BergaMet, to BergaMet’s satisfaction at the time of Closing, with true and complete copies of file histories, documents, certificates, office actions, correspondence, and other materials related to all Intellectual Property Assets.

(ii)              GCT owns all rights, title, and interest in and to the Intellectual Property Assets, free and clear of Encumbrances.

(m)             Legal Proceedings.

(i)                 There are no legal proceedings pending or, to GCT’s Knowledge, threatened against or by GCT (a) relating to or affecting GCT’s business operations; or (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement; and no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

(ii)              There are no outstanding and no unsatisfied judgments, penalties, or awards against, relating to, or affecting GCT’s ability to conduct its business operations.

(n)               Compliance with Laws; Permits.

(i)                 To GCT’s Knowledge, GCT has complied, and is now complying, with all Laws applicable to the conduct of its business operations as currently conducted.

(ii)              All Permits required for GCT to conduct its business operations as currently conducted, the lack of which would have a Material Adverse Effect, have been obtained by GCT and are valid and in full force and effect. All fees and charges with respect to such Permits as of the date hereof have been paid in full.

(o)               Employment Matters.

(i)                 As of the Effective Date and the Closing, (A) GCT has no employees, consultants or contactors, and (B) all commissions and bonuses payable to Employees, consultants, or contractors of GCT for services performed on or prior to the Effective Date and the Closing have been paid in full and there are no outstanding agreements, understandings, or commitments of GCT with respect to any commissions, bonuses or increases in compensation. GCT shall have the right, in its sole discretion, to employ, retain, or contract with any of such persons.

Page 12 of 30

(ii)              GCT is not a party to, or bound by, any collective bargaining or other Contract with a labor organization representing any of its Employees, and to GCT’s Knowledge, there are no labor organizations representing, purporting to represent or attempting to represent any Employee.

(iii)            To GCT’s Knowledge, GCT is and has been in compliance with all applicable Laws pertaining to employment and employment practices to the extent they relate to the Employees. To GCT’s Knowledge, all individuals characterized and treated by GCT as consultants or contractors of GCT’s business operations are properly treated as independent contractors under all applicable Laws.

(p)               Taxes.

(i)                 All Tax Returns required to be filed by GCT for any period prior to Closing have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. All Taxes due and owing by GCT (whether or not shown on any Tax Return) have been, or will be, timely paid.

(ii)              GCT has withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any Employee, independent contractor, creditor or other party, and complied with all information reporting and backup withholding provisions of applicable Law.

(iii)            No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of GCT.

(iv)             All deficiencies asserted, or assessments made, against GCT as a result of any examinations by any taxing authority have been fully paid.

(v)               GCT is not a party to any Action by any taxing authority. There are no pending or, to GCT’s Knowledge, threatened Actions by any taxing authority.

(vi)             There are no Encumbrances for Taxes upon any of GCT’s assets nor, to GCT’s Knowledge, is any taxing authority in the process of imposing any Encumbrances for Taxes on any of GCT’s assets (other than for current Taxes not yet due and payable).

(q)               Guaranties. GCT has not guaranteed any dividend, obligation, or indebtedness of any person; nor has any person guaranteed any dividend, obligation, or indebtedness of GCT.

(r)                Related Party Arrangements. Other than as contemplated by this Agreement, there are no obligations of GCT to its respective current or former members, shareholders, equity holders, managers, directors, officers, or employees.

Page 13 of 30

(s)                Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by GCT to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank, or other person with respect to the transactions contemplated by this Agreement.

 

(t)                 BergaMet Information. GCT acknowledges that BergaMet has made available to GCT the opportunity to ask questions of and receive answers from BergaMet’s manager and executive officers concerning the terms and conditions of this Agreement and the business and financial condition of BergaMet, and GCT has received to its satisfaction, such information about the business and financial condition of BergaMet and the terms and conditions of the Agreement as it has requested. GCT has carefully considered the potential risks relating to BergaMet and acquiring the BergaMet Units, and fully understands that BergaMet’s Business and the high degree of risk associated therewith.

 

2.3              Representations and Warranties of the BergaMet Members. Each BergaMet Member, severally and not jointly, represents and warrants to GCT as follows:

 

(a)               Ownership of the BergaMet Units. The BergaMet Member owns the number of BergaMet Units corresponding to the Exchange Ratio and the number of Exchange Shares issued to the BergaMet Member and stated in the BergaMet’s Joinder Agreement, free and clear of all liens, claims, rights, charges, encumbrances, and Security Interests of whatsoever nature or type, and the BergaMet Member represents and warrants that the BergaMet Units represent the entire ownership interest of the BergaMet Member in BergaMet.

 

(b)               Power of BergaMet Member to Execute Agreement. The BergaMet Member has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by the BergaMet Member and the consummation by the BergaMet Member of the transactions contemplated hereby have been (or at Closing will have been) duly authorized by all necessary action on the part of the BergaMet Member. This Agreement has been duly executed and when delivered by the BergaMet Member shall constitute a valid and binding obligation of the BergaMet Member, enforceable against the BergaMet Member, as applicable, in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity. The execution and delivery of this Agreement do not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, or acceleration of or “put” right with respect to any obligation or to a loss of a material benefit under, or result in the creation of any lien upon any of the properties or assets of the BergaMet Member under, (i) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, or license applicable to the BergaMet Member, its properties or assets; or (ii) subject to the governmental filings and other matters referred to in the following sentence, any

Page 14 of 30

judgment, order, decree, statute, law, ordinance, rule, regulation, or arbitration award applicable to the BergaMet Member, its properties or assets, other than any such conflicts would not prevent the BergaMet Member from consummating the transactions contemplated by this Agreement.

 

(c)               Investment. The BergaMet Member is acquiring the Exchange Shares for BergaMet Member’s own account, and not directly or indirectly for the account of any other person. The BergaMet Member is acquiring the Exchange Shares for investment and not with a view to distribution or resale thereof except in compliance with the Securities Act and any applicable state law regulating securities.

 

(d)               Registration of Securities. The BergaMet Member must bear the economic risk of investment for an indefinite period of time because the Exchange Shares have not been registered under the Securities Act and therefore cannot and will not be sold unless they are subsequently registered under the Securities Act or an exemption from such registration is available. GCT has made no representations, warranties, or covenants whatsoever as to whether any exemption from the Securities Act, including, without limitation, any exemption for limited sales in routine brokers’ transactions pursuant to Rule 144 under the Securities Act will become available. Transfer of the Exchange Shares has not been registered or qualified under any applicable state law regulating securities and therefore the Exchange Shares cannot and will not be sold unless it is subsequently registered or qualified under any such act or an exemption therefrom is available. GCT has made no representations, warranties or covenants whatsoever as to whether any exemption from any such act will become available.

 

(e)               Access to Information. The BergaMet Member acknowledges that GCT has made available to it the opportunity to ask questions of and receive answers from GCT’s management, including its officers and directors, concerning the terms and conditions of this Agreement and the business and financial condition of GCT, and the BergaMet Member has received such information about the business and financial condition of GCT and the terms and conditions of the Agreement as it has requested. The BergaMet Member understands that the Exchange Shares are speculative investments, which involve a high degree of risk of loss of the BergaMet Member’s entire investment.

 

(f)                Sophistication. The BergaMet Member further represents and warrants that the BergaMet Member has such business or financial expertise as to be able to protect the BergaMet Member’s own interests in connection with an investment in the Exchange Securities. The BergaMet Member further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of such investment. The BergaMet Member also represents that it has not been organized for the purpose of acquiring securities.

 

(g)               Acknowledgement of GCT’s Business. The BergaMet Member acknowledges and understands that GCT operates in the cannabis industry, specifically as it relates

Page 15 of 30

to full spectrum hemp oil, and that GCT’s products contain CBD and trace amounts of THC, and any change in current federal or state statutes, regulation or enforcement, or current federal or state statutes, regulation or enforcement may have a Material Adverse Effect on the business of GCT.

 

(h)               GCT Information. The BergaMet Member acknowledges that GCT has made available to it the opportunity to ask questions of and receive answers from GCT’s officers and directors concerning the terms and conditions of this Agreement and the business and financial condition of GCT, and the BergaMet Member has received to its satisfaction, such information about the business and financial condition of GCT and the terms and conditions of the Agreement as it has requested. The BergaMet Member has carefully considered the potential risks relating to GCT and acquiring the Exchange Shares, and fully understands that such securities are speculative investments, which involve a high degree of risk of loss of the BergaMet Member and its entire investment.

 

ARTICLE III
ADDITIONAL AGREEMENTS

 

3.1       Confidentiality. The Parties to this Agreement may have disclosed in the past, or may disclose in the future, (verbally, in writing and electronic format) to one or more of the other parties certain financial information, trade secrets, know-how, equipment, standards and specifications, proposed products and services, vendors, business plans, customer lists, prices, market and sales information and plans, and other non-public information about their businesses and operations (“Confidential Information”). For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each party agrees to receive the Confidential Information in strict confidence and not distribute, disclose, or disseminate any Confidential Information of another party except to its employees and contractors (under at least the same obligation of confidentiality) with a need to know, and to its financial or legal advisors.

 

3.2       Reasonable Efforts. Upon the terms and subject to the conditions set forth in this Agreement, each Party agrees to use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Exchange and the other transactions contemplated by this Agreement. GCT and BergaMet shall mutually cooperate in order to facilitate the achievement of the benefits reasonably anticipated from the Exchange.

 

3.4       Public Announcements. GCT and BergaMet will consult with each other before issuing, and provide each other the opportunity to review and comment upon, any press release or other public statements with respect to the transactions contemplated by this Agreement and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable law or court process. Each of the Parties hereto agree that the initial press release or subsequent releases to be issued with respect to the

Page 16 of 30

transactions contemplated by this Agreement shall be mutually agreed upon prior to the issuance thereof.

 

3.5       Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such expenses.

 

3.6       Financial Statements. Following the Closing, BergaMet will provide GCT with audited and unaudited financial statements, as required by Regulation S-X of the Exchange Act, in a timely manner such that Buyer may meet its filing obligations under the Exchange Act.

 

3.7       Further Issuances of Capital Stock. During the twelve (12)-month period immediately following the Closing, GCT shall not issue any shares of capital stock, or any other securities or rights convertible or exercisable into shares of capital stock, without the written consent of BergaMet Members who were issued a majority of the Exchange Shares issued at the Closing.

3.8       Tax Matters.

 

(a)       The BergaMet Members shall prepare (or cause to be prepared) all Tax Returns of BergaMet for Pre-Closing Tax Periods. If any such Tax Return is required to be filed by BergaMet after the Closing Date, Parent shall timely file such Tax Return. The BergaMet Members shall timely pay (or cause to be paid) to the applicable Governmental Entity all Taxes shown to be due on any Tax Return described in this Section 3.8(a).

 

(b)       In order to apportion appropriately any Taxes relating to Straddle Periods, the parties hereto will, to the extent permitted by applicable law, elect with the relevant Governmental Entity to treat for all purposes the Closing date as the last day of a taxable period of BergaMet (a “Short Period”). In any case where applicable law does not permit BergaMet to treat the Closing date as the last day of a Short Period, then for purposes of this Agreement, the portion of each Tax that is attributable to the operations of BergaMet for the period which would have qualified as a Short Period if such election had been permitted by applicable law (an “Interim Period”) shall be (i) in the case of any property Tax, ad valorem Tax, or exemption, allowance or deduction that is calculated on an annual basis (including, but not limited to, depreciation and amortization deductions), the total amount of such Tax or item for the period in question multiplied by a fraction, the numerator of which is the number of days in the Interim Period, and the denominator of which is the total number of days in such Straddle Period, and (ii) in the case of any Tax or item not described in clause (i), the Tax that would be due with respect to the Interim Period if such Interim Period were a Short Period determined based upon an interim closing of the books.

 

(c)       Notwithstanding anything to the contrary contained in this Agreement, the BergaMet Members shall have the sole right to control, through counsel of their own choosing,

Page 17 of 30

the defense or settlement of any claim or proceeding relating to a Tax matter for Pre-Closing Tax Periods.

 

(d)       Each party hereto agrees to co-operate fully, as and to the extent reasonably requested by the other party, in connection with the filing of any Tax Returns, any audit, litigation or other proceeding with respect to Taxes. The parties further agree, upon request, to use their commercially reasonable efforts to obtain any certificate or other document from any Governmental Entity or any other Person as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed with respect to the transactions contemplated in this Agreement.

 

(e)       For purposes of this Agreement: (x) “Taxes” shall mean (A) all federal, state, local or foreign taxes, charges, fees, imposts, levies or other assessments, including all net income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding, payroll, employment, social security, unemployment, excise, severance, stamp, occupation, property and estimated taxes, customs duties, fees, assessments and charges of any kind whatsoever, (B) all interest, penalties, fines, additions to tax or additional amounts imposed by any Governmental Entity in connection with any item described in clause (A), and (C) any liability in respect of any items described in clauses (A) or (B) payable by reason of contract, assumption, successor or transferee liability, operation of law, Treasury Regulation Section 1.1502-6(a) (or any similar provision of law) or otherwise; (y) “Tax Returns” shall mean any return, report, claim for refund, estimate, information return or statement or other similar document relating to or required to be filed or actually filed with any Governmental Entity with respect to Taxes, including any schedule or attachment thereto, and including any amendment thereof; and (z) “Pre-Closing Tax Period” means any taxable period ending on or before the Closing date.

 

ARTICLE IV
CONDITIONS PRECEDENT

 

4.1              Conditions to Each Party’s Obligation to Effect the Exchange. The obligation of each Party to effect the Exchange and otherwise consummate the transactions contemplated by this Agreement is subject to the satisfaction, at or prior to the Closing, of each of the following conditions:

 

(a)               No Restraints. No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Exchange shall have been issued by any court of competent jurisdiction or any other Governmental Entity having jurisdiction and shall remain in effect, and there shall not be any applicable legal requirement enacted, adopted, or deemed applicable to the Exchange that makes consummation of the Exchange illegal.

 

(b)               Governmental Approvals. All authorizations, consents, orders, declarations, or approvals of, or filings with, or terminations or expirations of waiting periods imposed by, any

Page 18 of 30

Governmental Entity having jurisdiction which the failure to obtain, make or occur would have a Material Adverse Effect on GCT or BergaMet shall have been obtained, made or occurred.

 

(c)               No Litigation. There shall not be pending or threatened any suit, action or proceeding before any court, Governmental Entity or authority (i) pertaining to the transactions contemplated by this Agreement; or (ii) seeking to prohibit or limit the ownership or operation by BergaMet, GCT or any of its subsidiaries, or to dispose of or hold separate any material portion of the business or assets of BergaMet or GCT.

 

(d)               Joinder Agreements. Each BergaMet Member shall have executed and delivered a Joinder Agreement.

 

4.2              Conditions Precedent to Obligations of GCT. The obligation of GCT to effect the Exchange and otherwise consummate the transactions contemplated by this Agreement are subject to the satisfaction, at or prior to the Closing, of each of the following conditions:

 

(a)               Representations, Warranties and Covenants. The representations and warranties of BergaMet and Decker in this Agreement shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to materiality or Material Adverse Effect, which representations and warranties as so qualified shall be true and correct in all respects) both when made and on and as of the Effective Date; and BergaMet and the BergaMet Members shall each have performed and complied in all material respects with all covenants, obligations and conditions of this Agreement required to be performed and complied with by each of them prior to the Effective Date.

 

(b)               Consents. GCT shall have received evidence, in form and substance reasonably satisfactory to it, that such licenses, permits, consents, approvals, authorizations, qualifications, and orders of governmental authorities and other third parties as necessary in connection with the transactions contemplated hereby have been obtained.

 

(c)               Cash. BergaMet shall have cash or cash equivalents of at least $800,000.

 

4.3              Conditions Precedent to Obligation of BergaMet and BergaMet Members. The obligation of BergaMet and BergaMet Members to effect the Exchange and otherwise consummate the transactions contemplated by this Agreement is subject to the satisfaction, at or prior to the Closing, of each of the following conditions:

 

(a)               Representations, Warranties, and Covenants. The representations and warranties of GCT in this Agreement shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to materiality or Material Adverse Effect, which representations and warranties as so qualified shall be true and correct in all respects) both when made and on and as of the Effective Date; and GCT shall have

Page 19 of 30

performed and complied in all material respects with all covenants, obligations, and conditions of this Agreement required to be performed and complied with by it prior to the Effective Date.

 

(b)               Consents. BergaMet shall have received evidence, in form and substance reasonably satisfactory to it, that such licenses, permits, consents, approvals, authorizations, qualifications, and orders of governmental authorities and other third parties as necessary in connection with the transactions contemplated hereby have been obtained.

 

(c)               GCT Capitalization. There shall be no outstanding shares of GCT’s Series A Convertible Preferred Stock, convertible notes, warrants or any other securities, instruments or rights convertible or exercisable into capital stock of GCT (or there shall be valid and binding agreements to effect the same at the Closing to the satisfaction of BergaMet). GCT’s common stock shall be the only class or series of GCT’s capital stock issued and outstanding or authorized for issuance by GCT. Without limiting the generality of the foregoing:

 

(i)                 Series A Convertible Preferred Stock. All holders of GCT’s outstanding Series A Convertible Preferred Stock shall have converted their shares into GCT common stock (or there shall be valid and binding agreements to effect the same at the Closing to the satisfaction of BergaMet).

 

(ii)              Convertible Notes. With respect to the convertible notes previously issued by GCT and outstanding immediately prior to Closing, GCT and such noteholders shall have entered into an agreement for such convertible notes to be, at or prior to the Closing, (A) paid and discharged in full at the Closing by the Closing Note Payoffs, for which the aggregate payoff does not exceed $353,907.97; (B) converted into GCT capital stock prior to the Closing; (C) amended to be the Restated-as-Nonconvertible Note for which the balance owing at Closing does not exceed $110,000.00; and/or (D) amended to be the Amended-and-Deferred Note for which the balance owing at Closing does not exceed $54,578.00; provided however a single convertible note, for which the note holder cannot be located and for which the balance owing at Closing does not exceed $6,749.69, plus interest, may continue to remain outstanding at and following the Closing.

 

(iii)            Warrants. There shall be no outstanding stock purchase warrants or similar rights to acquire capital stock of GCT, other than an aggregate of 42,800 warrants previously disclosed to BergaMet, each with an exercise price of at least $30.00 per share. Each such other warrant or right previously issued by GCT shall have either been (A) cancelled or (B) exercised prior to the Closing (or there shall be valid and binding agreements to effect the same at the Closing to the satisfaction of BergaMet).

 

 

Page 20 of 30

ARTICLE V
TERMINATION, RESCISSION, AMENDMENT, AND WAIVER

 

5.1       Termination.

 

(a)               This Agreement may be terminated:

 

(i)                 by mutual written consent of GCT and BergaMet;

(ii)              by either GCT or BergaMet if any Governmental Entity shall have issued an order, decree, or ruling or taken any other action permanently enjoining, restraining or otherwise prohibiting the Exchange and such order, decree, ruling, or other action shall have become final and non-appealable;

 

(iii)            on or before the date which is thirty (30) days after the Closing, by either Party if the other Party has breached any representation or warranty in this Agreement, and does not cure such breach within five (5) business days of notice of such breach; or

 

(iv)             by either GCT or BergaMet, if the Closing has not occurred on or before February 28, 2019.

 

5.2       Effect of Termination. In the event of termination of this Agreement by either BergaMet or GCT as provided in Section 5.1, this Agreement shall forthwith become void and have no effect, without any liability or obligation on the part of GCT, BergaMet, or the BergaMet Members. Nothing contained in this Section shall relieve any Party for any breach of the representations, warranties, covenants, or agreements set forth in this Agreement.

 

5.3       Amendment. This Agreement may not be amended except by an instrument in writing signed on behalf of (a) GCT; (b) BergaMet; and (c) BergaMet Members (i) if prior to the Closing, that hold a majority of the BergaMet Units to be exchanged for Exchange Shares pursuant to this Agreement, or (ii) if after the Closing, that held at the Closing a majority of the BergaMet Units were exchanged for Exchange Shares pursuant to this Agreement.

 

5.4       Return of Documents. In the event of termination or rescission of this Agreement for any reason, GCT and BergaMet will return to the other Party all of the other Party’s documents, work papers, and other materials (including copies) relating to the transactions contemplated in this Agreement, whether obtained before or after execution of this Agreement. GCT and BergaMet will not use any information so obtained from the other Party for any purpose and will take all reasonable steps to have such other Party’s information kept confidential.

 

Page 21 of 30

ARTICLE VI
INDEMNIFICATION AND RELATED MATTERS

 

6.1       Expiration and Survival of Representations, Warranties and Covenants.

 

(a)       The representations, warranties and covenants of BergaMet set forth in this Agreement or in any instrument delivered pursuant to this Agreement shall expire at the Closing, and BergaMet shall not have any liability thereafter with respect to any breach or inaccuracy in such representations, warranties or covenants. For the avoidance of doubt, the BergaMet Members shall have no liability or responsibility for the accuracy of the representations, warranties and covenants of BergaMet under this Agreement. The sole and exclusive remedy of GCT with respect to the breach of any representation, warranty or covenant of BergaMet shall be a termination of this Agreement prior to the Closing.

 

(b)       The representations and warranties of GCT set forth in this Agreement or in any instrument delivered pursuant to this Agreement shall survive until twenty four (24) months after the Closing (except for with respect to Taxes which shall survive for the applicable statute of limitations plus ninety (90) days, and covenants that by their terms survive for a longer period).

 

(c)        Except as otherwise provided in this Agreement, covenants set forth in this Agreement to be performed at or following the Closing shall survive the Closing.

 

(d)        The representations and warranties of each BergaMet Member set forth in Section 2.3 of this Agreement shall survive the Closing.

 

6.2       Indemnification.

 

(a)               GCT shall indemnify and hold BergaMet and the BergaMet Members, and their affiliates and assigns, harmless for, from and against any and all liabilities, obligations, damages, losses, deficiencies, costs, penalties, interest, and expenses (including, but not limited to, any and all expenses whatsoever reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever) (collectively, “Losses”) to which BergaMet, the BergaMet Members, or their affiliates and assigns, may become subject resulting from or arising out of any breach of a representation, warranty or covenant made by GCT as set forth herein.

 

(b)               Each BergaMet Member shall indemnify and hold GCT, and its affiliates and assigns, harmless for, from and against any and all Losses to which GCT, or its affiliates and assigns, may become subject resulting from or arising out of any breach of a representation, warranty, or covenant made by such BergaMet Member.

 

Page 22 of 30

6.3       Notice of Indemnification. Promptly after the receipt by any indemnified Party (the “Indemnitee”) of notice of the commencement of any action or proceeding against such Indemnitee, such Indemnitee shall, if a claim with respect thereto is or may be made against any indemnifying Party (the “Indemnifying Party”) pursuant to this Article VI, give such Indemnifying Party written notice of the commencement of such action or proceeding and give such Indemnifying Party a copy of such claim and/or process and all legal pleadings in connection therewith. The failure to give such notice shall not relieve any Indemnifying Party of any of its indemnification obligations contained in this Article VI, except where, and solely to the extent that, such failure actually and materially prejudices the rights of such Indemnifying Party. Such Indemnifying Party shall have, upon request within thirty (30) days after receipt of such notice, but not in any event after the settlement or compromise of such claim, the right to defend, at its own expense and by its own counsel reasonably acceptable to the Indemnitee, any such matter involving the asserted liability of the Indemnitee; provided, however, that if the Indemnitee determines that there is a reasonable probability that a claim may materially and adversely affect it, other than solely as a result of money payments required to be reimbursed in full by such Indemnifying Party under this Article VI or if a conflict of interest exists between Indemnitee and the Indemnifying Party, the Indemnitee shall have the right to defend, compromise or settle such claim or suit; and, provided, further, that such settlement or compromise shall not, unless consented to in writing by such Indemnifying Party, which shall not be unreasonably withheld, be conclusive as to the liability of such Indemnifying Party to the Indemnitee. In any event, the Indemnitee, such Indemnifying Party and its counsel shall cooperate in the defense against, or compromise of, any such asserted liability, and in cases where the Indemnifying Party shall have assumed the defense, the Indemnitee shall have the right to participate in the defense of such asserted liability at the Indemnitee’s own expense. In the event that such Indemnifying Party shall decline to participate in or assume the defense of such action, prior to paying or settling any claim against which such Indemnifying Party is, or may be, obligated under this Article VI to indemnify an Indemnitee, the Indemnitee shall first supply such Indemnifying Party with a copy of a final court judgment or decree holding the Indemnitee liable on such claim or, failing such judgment or decree, the terms and conditions of the settlement or compromise of such claim. An Indemnitee’s failure to supply such final court judgment or decree or the terms and conditions of a settlement or compromise to such Indemnifying Party shall not relieve such Indemnifying Party of any of its indemnification obligations contained in this Article VI, except where, and solely to the extent that, such failure actually and materially prejudices the rights of such Indemnifying Party. If the Indemnifying Party is defending the claim as set forth above, the Indemnifying Party shall have the right to settle the claim only with the consent of the Indemnitee.

 

6.4       Remedies. If GCT has any indemnification liability to the BergaMet Members under this Agreement, the BergaMet Member shall have the option, but not the obligation, to require that GCT satisfy such indemnification obligation through the issuance of additional GCT common stock having aggregate fair market value equal to the indemnification obligation amount. If the GCT common stock is then publicly traded, its fair market value per share shall be the

Page 23 of 30

average closing price for the ten (10) trading day period ending five (5) trading days prior to the date of determination of fair market value. For the absence of doubt, the foregoing remedy shall be cumulative with, and not lieu of, any other remedy at law, equity or otherwise.

 

ARTICLE VII
GENERAL PROVISIONS

 

7.1       Notices. Any and all notices and other communications hereunder shall be in writing and shall be deemed duly given to the Party to whom the same is so delivered, sent or mailed at addresses and contact information set forth below (or at such other address for a Party as shall be specified by like notice). Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be deemed given and effective on the earliest of: (a) on the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:00 p.m. (Pacific Time) on a business day; (b) on the next business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a business day or later than 5:00 p.m. (Pacific Time) on any business day; (c) on the second business day following the date of mailing, if sent by a nationally recognized overnight courier service; or (d) if by personal delivery, upon actual receipt by the Party to whom such notice is required to be given.

 

If to GCT:

Grey Cloak Tech, Inc.

10300 W. Charleston Blvd., Suite 13-378

Las Vegas, NV 89135

Attn: William Bossung

Email: wbossung@yahoo.com

 

with a copy to (which shall not constitute notice):

 

Clyde Snow & Sessions, PC
Attn: Brian A. Lebrecht
201 South Main Street, Suite 1300
Salt Lake City, UT 84111
Email: bal@clydesnow.com

 

If to BergaMet:

BergaMet NA, LLC

11500 Longwater Chase Ct.

Fort Myers, FL 33908

Attn: Jay W. Decker

 

with a copy to (which shall not constitute notice):

 

Page 24 of 30

Fennemore Craig, P.C.

Attn: Aaron Cain

2394 East Camelback Road, Suite 600

Phoenix, AZ 85016

Email: acain@fclaw.com

 

If to the

BergaMet Members:

c/o Jay W. Decker

11500 Longwater Chase Ct.

Fort Meyers, FL 33908

with a copy to (which shall not constitute notice):

 

Fennemore Craig, P.C.

Attn: Aaron Cain

2394 East Camelback Road, Suite 600

Phoenix, AZ 85016

Email: acain@fclaw.com

 

7.2       Definitions. For purposes of this Agreement:

 

(a)               an “Affiliate” of any person means another person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first person;

 

(b)               Intellectual Property” means all of the following and similar intangible property and related proprietary rights, interests and protections, however arising, pursuant to the Laws of any jurisdiction throughout the world: (a) trademarks, service marks, assumed names, trade names, brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered, unregistered or arising by Law, and all registrations and applications for registration of such trademarks, including intent-to-use applications, and all issuances, extensions and renewals of such registrations and applications; (b) internet domain names, whether or not trademarks, registered in any generic top level domain by any authorized private registrar or Governmental Authority; (c) original works of authorship in any medium of expression, whether or not published, all copyrights (whether registered, unregistered or arising by Law), all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications; (d) confidential information, formulas, designs, devices, technology, know-how, research and development, inventions, methods, processes, compositions and other trade secrets, whether or not patentable; (e) patented and patentable designs and inventions, all design, plant and utility patents, letters patent, utility models, pending patent applications and provisional applications and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals of such patents and applications; and (f) any manuals relating to operations, training, employment, including materials provided to any licensees.

 

Page 25 of 30

(c)               Intellectual Property Assets” means all Intellectual Property that is owned by GCT and used in or necessary for the conduct of its business.

 

(d)               Knowledge” shall mean actual then-current knowledge of the applicable Party or any director or executive officer of the applicable Party;

 

(e)               Material Adverse Effect” means, when used in connection with BergaMet or GCT, any change or effect that either individually or in the aggregate with all other such changes or effects is materially adverse to the business, assets, properties, condition (financial or otherwise) or results of operations of such Party and its subsidiaries taken as a whole (after giving effect in the case of GCT to the consummation of the Exchange);

 

(f)                Ordinary course of business” means the ordinary course of business consistent with past custom and practice (including with respect to quantity and frequency);

 

(g)               Permits” means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Entities.

 

(h)               Person” means an individual, corporation, partnership, joint venture, association, trust, unincorporated organization or other entity;

 

(i)                 Security Interest” means any mortgage, pledge, lien, encumbrance, deed of trust, lease, charge, right of first refusal, easement, servitude, proxy, voting trust or agreement, transfer restriction under any shareholder or similar agreement or any other security interest, other than (i) mechanic’s, materialmen’s, and similar liens; (ii) statutory liens for taxes not yet due and payable; (iii) purchase money liens and liens securing rental payments under capital lease arrangements; (iv) pledges or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other similar social security legislation; and (v) encumbrances, security deposits or reserves required by law or by any Governmental Entity.

 

7.3       Interpretation. When a reference is made in this Agreement to a Section, Exhibit, or Schedule, such reference shall be to a Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes,” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.”

 

Page 26 of 30

7.4       Entire Agreement; No Third-Party Beneficiaries. This Agreement and the other agreements referred to herein constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter of this Agreement. This Agreement is not intended to confer upon any person other than the Parties any rights or remedies.

 

7.5       Governing Law/Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. Except as otherwise required by applicable law, each party hereby irrevocably: (a) submits in any legal proceeding relating to this Agreement to the exclusive jurisdiction of any state or United States court of competent jurisdiction sitting in the State of Nevada and agrees to suit being brought in such courts; and (b) waives any objection it may now or hereafter have to the venue of such proceeding in any such court or that such proceeding was brought in an inconvenient forum.

 

7.6       Assignment. Neither this Agreement nor any of the rights, interests, or obligations under this Agreement shall be assigned, in whole or in part, by operation of law or otherwise by any of the Parties without the prior written consent of the other Parties. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns.

 

7.7       Enforcement. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any state or federal court located in the State of Nevada, this being in addition to any other remedy to which they are entitled at law or in equity. In addition, each of the Parties hereto (a) agrees that it will not attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave from any such court; and (b) agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement in any state court other than such court.

 

7.8       Severability. Whenever possible, each provision or portion of any provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law but if any provision or portion of any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or portion of any provision in such jurisdiction, and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.

 

Page 27 of 30

7.9       Counterparts. This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one Party, but all such counterparts taken together will constitute one and the same Agreement. This Agreement, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “Electronic Delivery”), shall be treated in all manner and respects as an original agreement or instrument, and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party hereto, each other Party hereto shall re-execute original forms hereof and deliver them in person to all other Parties. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

7.10       Attorneys’ Fees. In the event any suit or other legal proceeding is brought for the enforcement of any of the provisions of this Agreement, the Parties hereto agree that the prevailing Party or Parties shall be entitled to recover from the other Party or Parties upon final judgment on the merits reasonable attorneys’ fees, including attorneys’ fees for any appeal, and costs incurred in bringing such suit or proceeding.

 

[remainder of page intentionally left blank; signature page to follow]

 


Page 28 of 30

IN WITNESS WHEREOF, the undersigned have caused their duly authorized officers to execute this Agreement as of the date first above written.

 

  GCT
   
  Grey Cloak Tech Inc.,
  a Nevada corporation
   
   
  /s/ Kevin Pitts
  By: Kevin Pitts
  Its: Chief Executive Officer

 

 

  BergaMet
   
  BergaMet NA, LLC,
  a Delaware limited liability company
   
   
  /s/ Jay W. Decker
  By: Jay W. Decker
  Its: Manager

 

 

Page 29 of 30

 

 


EXHIBITS
A BergaMet Members
B Form of BergaMet Representation Certificate
C Form of BergaMet Officer’s Certificate
D Joinder Agreement
E Form of GCT Representation Certificate
F Form of GCT Officer’s Certificate
I Board Members and Officers
J GCT’s Post-Closing Capitalization

 

Page 30 of 30

Exhibit A

 

BergaMet Members

 

Jay W. Decker

Shelton Decker

Logan Decker

Jerry Haase

James Ehrich

Randy Looper

Martin Bridge

Bill Croyle

 

 
 

Exhibit B

 

Form of BergaMet Representation Certificate

 

(see attached)

 

 
 

Exhibit C

 

Form of BergaMet Officer’s Certificate

 

(see attached)

 

 
 

Exhibit D

 

Joinder Agreement

 

(see attached)

 

 
 

Exhibit E

 

Form of GCT Representation Certificate

 

(see attached)

 

 
 

Exhibit F

 

Form of GCT Officer’s Certificate

 

(see attached)

 

 
 

Exhibit G

 

Members of the Board of Directors

 

GCT’s Board of Directors will consist of the following, effective at Closing:

 

Kevin Pitts (existing), William Bossung (existing) and Sanjeev Javia.

 

Executive Officer Appointments

 

Effective at Closing, the following individuals will be appointed to the positions indicated:

 

Sanjeev Javia – Chief Executive Officer and President

 

Kevin Pitts – Chief Operating Officer

 

William Bossung will remain in his position as GCT’s Chief Financial Officer.

 

Kevin Pitts will resign his positions of Chief Executive Officer and President effective at Closing.

 

 
 

Exhibit H

 

GCT’s Post-Closing Capitalization

 

 

Total Issued and Outstanding     7,097,406       5.84 %
Matthew Grabau     350,000       0.29 %
Crown Bridge Conversion     354,000       0.29 %
Preferred Stock Conversions     15,592,986       12.82 %
Debt Conversions     806,015       0.66 %
BergaMet Members     97,409,678       80.10 %
  Total     121,610,085       100.00 %

 

 

NOTE SATISFACTION AGREEMENT

 

This Note Satisfaction Agreement (this “Agreement”) is entered into on [Ÿ], 2019 (the “Effective Date”) by and between Grey Cloak Tech Inc., a Nevada corporation (the “Company”), and [Ÿ], a [Ÿ] (“Holder”). Each of the Company and Holder may be referred to as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Company is obligated to Holder under a convertible promissory note dated [Ÿ] in the original principal amount of $[Ÿ] (the “Note”); and

 

WHEREAS, the Company has offered to deliver to Holder the sum of $[Ÿ] (the “Payoff Amount”) in full satisfaction of the Note, and Holder is willing to accept same.

 

NOW, THEREFORE, for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

AGREEMENT

 

1.                  If, prior to 8:00 pm MT on February 15, 2019 (the “Payoff Period”), the Company delivers the Payoff Amount to Holder, then Holder acknowledges that the Note will be satisfied and discharged in full and the Company will have no further obligations to Holder.

 

2.                  Holder covenants that from and after the Effective Date, unless and until this Agreement is terminated pursuant to paragraph 3, below, it will not exercise its conversion rights under the Note.

 

3.                  If the Payoff Amount is not paid to Holder within the Payoff Period, then this Agreement shall automatically terminate with no further obligations between the Parties, and the Note shall remain in full force and effect.

 

4.                  Holder represents and warrants to the Company that (a) Holder is the sole owner of the Note, (b) Holder has not transferred or granted any interest in or to the Note to any third party, and (c) Holder holds the Note free and clear of all liens, claims, rights, charges, encumbrances, and security interests of whatsoever nature or type.

 

5.                  This Agreement will be governed by the laws of the state, and venue for any cause of action brought under this Agreement will be, as set forth in the Note.

 

Page 1 of 3

6.                  This Agreement will be binding upon and inure to the benefit of the Parties and their respective heirs, legal representatives and assigns. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company to assume all of the Company’s obligations under this Agreement. Such assumption will not release the Company from its obligations under this Agreement.

 

7.                  The provisions of this Agreement will be deemed severable, and if any part of any provision is held illegal, void or invalid under applicable law, such provision may be changed to the extent reasonably necessary to make the provision, as so changed, legal, valid and binding. If any provision of this Agreement is held illegal, void or invalid in its entirety, the remaining provisions of this Agreement will not in any way be affected or impaired but will remain binding in accordance with their terms.

 

8.                  This Agreement contains the entire agreement between the Parties and supersedes any and all agreements, either oral or written, between the Parties hereto with respect to the Note. Each Party to this Agreement acknowledges that no representations, inducements, promises or agreements, orally or otherwise, have been made by any Party, or anyone acting on behalf of any party, which are not embodied herein, and that no other agreement, statement or promise not contained in this Agreement shall be effective only if it is in writing and signed by both Parties. This Agreement may only be amended, modified or changed by an agreement in writing signed by both Parties. Each Party hereto shall make, execute, acknowledge and deliver such other instruments and documents, and take all such other actions as may be reasonably required in order to effectuate the purposes of this Agreement and to consummate the transactions contemplated hereby.

 

9.                  This Agreement may be signed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[remainder of page intentionally left blank; signature page to follow]

 

Page 2 of 3

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

“Company” “Holder”
   
Grey Cloak Tech Inc. [Ÿ]
   
________________________ ________________________
By: Kevin Pitts By:
Its: President Its:

 

Page 3 of 3

PREFERRED STOCK CONVERSION AGREEMENT

 

This Preferred Stock Conversion Agreement (this “Agreement”) is entered into on [•], 2019 by and between Grey Cloak Tech Inc., a Nevada corporation (the “Company”), and [•], a [•] (the “Shareholder”). Each of the Company and the Shareholder shall be referred to as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Shareholder is the holder of [•] shares of the Company’s Series A Convertible Preferred Stock (the “Preferred Shares”);

 

WHEREAS, the Company plans to enter into a Share Exchange Agreement whereby the Company will acquire BergaMet NA, LLC (“BergaMet”) and will issue shares of the Company’s common stock to BergaMet’s unitholders whereby the BergaMet unitholders will own 80% of the Company’s outstanding capital stock immediately thereafter (after conversion of all outstanding preferred stock issued by the Company and conversion or satisfaction of all convertible notes issued by the Company) (the “Merger”);

 

WHEREAS, the Company and the Shareholder desire for the Preferred Shares to be automatically converted into shares of the Company’s common stock upon completion of the Merger.

 

NOW, THEREFORE, for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

AGREEMENT

 

1.                  Conversion of Preferred Shares. The Parties agree that upon the closing of the Merger, each of the Preferred Shares will be automatically converted into eighteen (18) shares of common stock of the Company. Each Party hereby agrees to release the other Party from any and all claims related to the Preferred Shares upon their conversion as set forth in this Agreement.

 

2.                  Termination. This Agreement will automatically terminate and the Parties will be relieved of all obligations hereunder if the Merger is not completed by 8:00 pm MT on February 15, 2019. In the event that this Agreement is terminated pursuant to this Section 2, then this Agreement will have no effect on the Preferred Shares.

 

3.                  Governing Law and Venue. This Agreement will be governed by the laws of the state, and venue for any cause of action brought under this Agreement will be, as set forth in the Preferred Shares Certificate of Designation.

 

Page 1 of 3

4.                  Successors.

 

(a)               This Agreement will be binding upon and inure to the benefit of the Parties and their respective heirs, legal representatives and assigns.

 

(b)               The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company to assume all of the Company’s obligations under this Agreement. Such assumption will not release the Company from its obligations under this Agreement.

 

5.                  Severability. The provisions of this Agreement will be deemed severable, and if any part of any provision is held illegal, void or invalid under applicable law, such provision may be changed to the extent reasonably necessary to make the provision, as so changed, legal, valid and binding. If any provision of this Agreement is held illegal, void or invalid in its entirety, the remaining provisions of this Agreement will not in any way be affected or impaired but will remain binding in accordance with their terms.

 

6.                  Entire Agreement. This Agreement contains the entire agreement between the Parties and supersedes any and all agreements, either oral or written, between the Parties hereto with respect to the Preferred Shares. Each Party to this Agreement acknowledges that no representations, inducements, promises or agreements, orally or otherwise, have been made by any Party, or anyone acting on behalf of any party, which are not embodied herein, and that no other agreement, statement or promise not contained in this Agreement shall be effective only if it is in writing and signed by both Parties. This Agreement may only be amended, modified or changed by an agreement in writing signed by both Parties. Each Party hereto shall make, execute, acknowledge and deliver such other instruments and documents, and take all such other actions as may be reasonably required in order to effectuate the purposes of this Agreement and to consummate the transactions contemplated hereby.

 

7.                  Counterparts. This Agreement may be signed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[remainder of page intentionally left blank; signature page to follow]

 

Page 2 of 3

IN WITNESS WHEREOF, the Parties have executed this Preferred Stock Conversion Agreement on the date written above.

 

Company Shareholder
   
Grey Cloak Tech Inc., [Ÿ]
a Nevada corporation  
   
   
_________________________ _________________________
By: William Bossung By:
Its: Chief Financial Officer Its:

 

Page 3 of 3

EXHIBIT 31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

 

I, Kevin “Duke” Pitts, certify that:

 

I have reviewed this Quarterly Report on Form 10-Q of Grey Cloak Tech Inc.;

 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)       Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 28, 2020    
    /s/ Kevin Pitts
  By: Kevin “Duke” Pitts
    President
 

EXHIBIT 31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

I, William Bossung, certify that:

 

I have reviewed this Quarterly Report on Form 10-Q of Grey Cloak Tech Inc.;

 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)       Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 28, 2020    
    /s/ William Bossung
  By William Bossung
    Chief Financial Officer
 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report of Grey Cloak Tech Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Kevin “Duke” Pitts, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)        The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)        Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: May 28, 2020    
    /s/ Kevin Pitts
  By: Kevin “Duke” Pitts
    President

  

A signed original of this written statement required by Section 906 has been provided to Grey Cloak Tech Inc., and will be retained by Grey Cloak Tech Inc., and furnished to the Securities and Exchange Commission or its staff upon request. 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report of Grey Cloak Tech Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, William Bossung, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)        The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)        Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: May 28, 2020    
    /s/ William Bossung
  By: William Bossung
    Chief Financial Officer

 

 

A signed original of this written statement required by Section 906 has been provided to Grey Cloak Tech Inc., and will be retained by Grey Cloak Tech Inc., and furnished to the Securities and Exchange Commission or its staff upon request.